Form 4: Apellis Pharmaceuticals Chief Scientific Officer Sells Shares to Cover Tax Withholding

Pascal Deschatelets, Chief Scientific Officer of Apellis Pharmaceuticals, sold 3,948 shares of common stock on January 22, 2025, to cover tax obligations related to released Restricted Stock Units.

Summary

• On January 22, 2025, Pascal Deschatelets, the Chief Scientific Officer of Apellis Pharmaceuticals, sold 3,948 shares of the company's common stock.
• The shares were sold at a price of $30.4255 per share.
• This transaction was executed to cover tax withholding obligations associated with Restricted Stock Units that vested on January 21, 2025.
• Following the transaction, Deschatelets directly owns 1,148,542 shares of Apellis Pharmaceuticals.

Sentiment

Score: 5

Explanation: Neutral sentiment as the transaction is related to tax obligations and doesn't necessarily reflect a change in the executive's confidence in the company.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies, often related to compensation and tax obligations. Monitoring these transactions can provide insights into management's perspective on the company's value, although sales to cover taxes are generally less indicative of sentiment.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to have a significant impact given the reason for the sale.

Key Dates

Keywords

Apellis Pharmaceuticals, Pascal Deschatelets, Chief Scientific Officer, stock sale, Form 4, insider trading, Restricted Stock Units, tax withholding